Skip to main content
. 2015 Aug 28;3(1):47–68. doi: 10.1007/s40487-015-0009-4

Table 1.

Risk stratification of multiple myeloma by cytogenetic abnormalities

High risk Intermediate risk Standard risk
Deletion 17p t(4;14) t(11;14)
t(14;16) 1q gain t(6;14)
t(14;20) Metaphase deletion 13 All other cytogenetic abnormalities not high- or intermediate-risk
GEP high risk signature High plasma cell proliferative rate S-phase (≥3%)